NEJM: Prevention of 1/3 of major cardiovascular events Autumn daffodils to treat chronic coronary heart disease added evidence.

Screenshot Source: New England Journal of Medicine Large Trial Latest Results This trial was conducted in more than 5,522 patients aged 35-82 (average 66 years) with chronic coronary heart disease, most of whom were men (84.7%), about half had high blood pressure, 18.2% had diabetes and 84.4% had a history of acute coronary artery syndrome.
on the basis of standard therapy, subjects were randomly grouped to receive 0.5 mg of autumn daffodils or placebos once a day.
follow-up time was 28.6 months.
6.8 percent of patients in the autumn daffodil group and 9.6 percent of placebo patients experienced coronary artery hemodynamic reconstruction due to cardiovascular death, heart attack, ishemotic stroke, or isnemic problems, respectively.
the main endpoint, autumn daffodils significantly reduced the risk by 31%.
Compared to placebos, alkaloids were also associated with a significant reduction in the incidence of five important secondary endpoint events: cardiovascular death, heart attack or ishemic stroke (4.2% vs 5.7%), a 28% reduction in the risk of alkaloid group; 33%; cardiovascular death or heart attack (3.6% vs 5.0%), 29% reduction in risk of alkaloid group in autumn, reconstruction of blood transport due to isnemic problems (4.9% vs 6.4%), 25% reduction in risk of acacid group in autumn, 3.0% vs 4.2% risk in the risk of acacid group in autumn.
have observed that the benefits of alkaloids in autumn have been evident early in the study and have accumulated over time, more significantly.
, the preventive effects of alkaloids were consistent across 13 subgroups, including those with or without a history of hypertension, diabetes or acute coronary artery syndrome.
In terms of safety, the severe adverse reactions in the akidific and placebo groups were similar, including hospitalization for infection (5.0% vs 5.2%), pneumonia (1.7% vs 2.0%) or gastrointestinal causes (1.9% vs 1.8%).
toxicity events occurred in 3 cases per group.
researchers point out that there may be potentially adverse interactions between kramycin and aphdobinal, but the use of low-dose alkaloids and full-dose statins appears to be safe. Dr Mark Nidorf, of GenesisCare, a leading Australian clinic and one of the lead authors of the
, told the ESC conference: "Akihy daffodils do have a broad and consistent effect in a range of clinical subgroups, demonstrating that alkaloids are effective in improving cardiovascular outcomes in these patients we receive daily.
" He added that in this trial, the majority (68.2%) of the subjects who had under been subjected to coronary arterial hemodynamic reconstruction due to acute coronary artery syndrome occurred in the random group of 24 months of the trial, which meant that the subjects were not "pre-selected high-risk groups", but rather "very stable" groups of patients, similar to those who went to medical facilities on a daily basis for regular check-ups or follow-up visits.
call for a change in clinical practice As early as seven years ago, Dr. Nidorf led a team that demonstrated in a small trial of 500 patients that low doses of alkaloids could be beneficial to patients with coronary heart disease.
, a number of trials around the world have been conducted to explore the use of autumn daffodils for cardiovascular disease.
Regarding the potential mechanism by which the anti-inflammatory drug Akita is used to prevent cardiovascular disease, Dr. Nidorf said, "We now know that when cholesterol enters the artery wall, it spontaneously forms crystals, like gyrocrys, which can cause a low inflammatory response, leading to long-term scarring of the arteries."
when this inflammation worsens, it can lead to plaque rupture, which can lead to heart attacks and strokes.
" is now again positive, in Dr. Nidorf's view, "it's groundbreaking, practice-changing results."
the long-term use of low doses of daffodils is safe and does not increase the risk of bleeding or hypotension, so it is suitable for use with existing therapies and may become a cornerstone therapy for coronary heart disease patients with aspirin and statins.
, autumn daffodils are cheap and widely available.
Dr. Paul Ridker, Director of the Cardiovascular Disease Prevention and Control Center at Brigham and Women's Hospital, commented, "The results of three important double-blind placebo-controlled trials, including CANTOS, COLCOT, and LoDoCo2, are highly consistent, which is enough to change clinical practice."
" References: s1. Stefan M. Nidorf, et al., (2020). Colchicine in Patients with Chronic Coronary Disease. N Engl J Med, DOI: 10.1056/NEJMoa2021372 ( 2 ) LoDoCo2: Added Steam for Colchicine as Secondary Prevention. Retrieved September 3, 2020, from. Retrieved September 3, 2020, from the common medicine used to treat gout found to prevent progression of coronary disease. Retrieved September 3, 2020, from Original Title: NEJM: Prevention of 1/3 Major Cardiovascular Events, Gyroph's Old Drug Akikon to Treat Chronic Coronary Heart Disease Adds Evidence.